Download PDF
Aktuelle Dermatologie 2018; 44(03): 92-99
DOI: 10.1055/s-0043-115677
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Hidradenitis suppurativa (Acne inversa) – Aktuelles zu Komorbidität und Therapie

Hidradenitis Suppurativa (Acne inversa) – Current Status on Comorbidity and Therapy
S. Wilden
Hautklinik der Universitätsmedizin Mainz
,
H. Schepler
Hautklinik der Universitätsmedizin Mainz
,
E. von Stebut
Hautklinik der Universitätsmedizin Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
05 December 2017 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Lange unter der Rubrik „orphan disease“ gelistet, erfuhr die Hidradenitis suppurativa (HS) zuletzt mit der Zulassung von Adalimumab neue Aufmerksamkeit. Was mit einzelnen Knoten und Abszessen anfängt, endet unter mangelnder Behandlung nicht selten in ausgedehnter Fistelbildung und Vernarbung, die zum Teil mit erheblichen Bewegungseinschränkungen, sozialem Rückzug und Isolation einhergehen.

In Deutschland geht man derzeit von einer Prävalenz von etwa 1 % aus [1] [2]. Somit kommt diese multifaktoriell bedingte Erkrankung ähnlich häufig vor wie die Psoriasis, doch bekommt sie bei weitem nicht die gleiche Aufmerksamkeit. Vielleicht ist dies auch der Tatsache geschuldet, dass das Therapieangebot mit (noch) nur einer zugelassenen medikamentösen Therapie (Adalimumab) sehr viel kleiner ausfällt als beispielsweise das der Psoriasis.

Abstract

Long considered an orpan disease, Hidradenitis suppurativa (HS) has recently gained new attention since the approval of Adalimumab for its treatment. What generally starts with single nodules and abcesses, often ends in extensive fistulation and scarring if treated inadequately and is frequently accompanied by significant restrictions of mobility, social withdrawal and isolation.

It is presumed that in Germany the prevalence is about 1 % [1] [2], therefore this multifactorial disease has an incidence almost equal to that of psoriasis, although it doesn’t receive the same attention. This might be due to the fact that the available therapies with currently only one approved medical option (Adalimumab) are rather limited when compared to the numerous options for psoriasis.

 

  • Literatur

  • 1 Revuz JE, Canoui-Poitrine F, Wolkenstein P. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601
    CrossrefPubMedGoogle Scholar
  • 2 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194
    CrossrefPubMedGoogle Scholar
  • 3 Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194: 325-328
    CrossrefPubMedGoogle Scholar
  • 4 Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-769
    CrossrefPubMedGoogle Scholar
  • 5 Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G. Hrsg. Acne and related disorders. London: Martin Dunitz; 1989: 345-357
    Google Scholar
  • 6 Danby FW, Jemec GB, Marsch WCh. et al. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013; 168: 1034-1039
    CrossrefPubMedGoogle Scholar
  • 7 Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34: 994-999
    CrossrefPubMedGoogle Scholar
  • 8 von Laffert M, Helmbold P, Wohlrab J. et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-537
    CrossrefPubMedGoogle Scholar
  • 9 Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135
    PubMedGoogle Scholar
  • 10 van der Zee HH, Laman JD, Boer J. et al. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 10: 735-739
    PubMedGoogle Scholar
  • 11 Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 2014; 28: 1013-1027
    CrossrefPubMedGoogle Scholar
  • 12 van der Zee HH, de Ruiter L, van den Broecke DG. et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298
    CrossrefPubMedGoogle Scholar
  • 13 Riis PT, Søeby K, Saunte DM. et al. Patients With Hidradenitis Suppurativa Carry a Higher Systemic Inflammatory Load Than Other Dermatological Patients. Arch Dermatol Res 2015; 307: 885-889
    CrossrefPubMedGoogle Scholar
  • 14 Pascoe VL, Kimball AB. Hidradenitis suppurativa: current progress and future questions. JAMA Dermatol 2014; 150: 1263-1264
    CrossrefPubMedGoogle Scholar
  • 15 Shlyankevich J, Chen AJ, Kim GE. et al. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71: 1144-1150
    CrossrefPubMedGoogle Scholar
  • 16 Wolkenstein P, Loundou A, Barrau K. et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623
    CrossrefPubMedGoogle Scholar
  • 17 Kimball AB, Jemec GB, Yang M. et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171: 434-442
    PubMedGoogle Scholar
  • 18 Zouboulis CC, Tzellos T, Kyrgidis A. et al. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol 2017; DOI: 10.1111/bjd.15748. in press
    PubMedGoogle Scholar
  • 19 Naldi L. Epidemiology. In: Jemec G, Revuz J, Leyden JJ. eds. Hidradenitis Suppurative. Berlin: Springer; 2006: 58-64
    Google Scholar
  • 20 Dufour DN, Bryld LE. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology 2010; 220: 323-325
    CrossrefPubMedGoogle Scholar
  • 21 Cesko E, Koerber A, Dissemond J. Smoking and obesity are associated factors in acne inversa: results of a retrospective investigation in 100 patients. Eur J Dermatol 2009; 19: 490-493
    CrossrefPubMedGoogle Scholar
  • 22 König A, Lehmann C, Rompel R. et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198: 261-264
    CrossrefPubMedGoogle Scholar
  • 23 Hana A, Booken D, Henrich C. et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80: 2214-2220
    CrossrefPubMedGoogle Scholar
  • 24 Kurzen H, Kurokawa I, Jemec GB. et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008; 17: 455-472
    CrossrefPubMedGoogle Scholar
  • 25 Gold DA, Reeder VJ, Mahan MG. et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 699-703
    CrossrefPubMedGoogle Scholar
  • 26 Miller IM, Ellervik C, Vinding GR. et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150: 1273-1280
    CrossrefPubMedGoogle Scholar
  • 27 Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol 2016; 152: 429-434
    CrossrefPubMedGoogle Scholar
  • 28 Craig A. Elmets, MD reviewing Egeberg A et al. JAMA Dermatol 2016 Feb 17 . http://www.jwatch.org/na40561/2016/03/15/increased-risk-cardiovascular-adverse-events-patients-with
    PubMedGoogle Scholar
  • 29 Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11: 125-131
    CrossrefPubMedGoogle Scholar
  • 30 Schneider-Burrus S, Witte-Haendel E, Christou D. et al. High Prevalence of back pain and axial spondyloarthropathy in patients with Hidradenitis Suppurativa. Dermatology 2016; 232: 606-612
    CrossrefPubMedGoogle Scholar
  • 31 Richette P, Molto A, Viguier M. et al. Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study. J Rheumatol 2014; 41: 490-494
    CrossrefPubMedGoogle Scholar
  • 32 Kurek A, Johanne Peters EM, Sabat R. et al. Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 2013; 11: 743-750
    PubMedGoogle Scholar
  • 33 Essmann S, Jemec G. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venerol 2011; 91: 328-332
    CrossrefPubMedGoogle Scholar
  • 34 Guillem P. Psychological support for patients with hidradenitis suppurativa. Berlin: EHSF Symposium; 2016
    Google Scholar
  • 35 Verdolini R, Clayton N, Smith A. et al. Metformin for the treatment of Hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venererol 2013; 27: 1101-1108
    PubMedGoogle Scholar
  • 36 Mühlstädt M, Bechara FG, Kunte C. Acne inversa (hidradenitis suppurativa). From diagnosis to therapy. Hautarzt 2013; 64: 55-61
    CrossrefPubMedGoogle Scholar
  • 37 Mrowietz U. Tagesnotiz. JDDG 2016; 14: 650
    CrossrefPubMedGoogle Scholar
  • 38 Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22: 325-328
    CrossrefPubMedGoogle Scholar
  • 39 Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-974
    CrossrefPubMedGoogle Scholar
  • 40 Gener G, Canoui-Poitrine F, Revuz JE. et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-154
    CrossrefPubMedGoogle Scholar
  • 41 Kimball AB, Okun MM, Williams DA. et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375: 422-434
    CrossrefPubMedGoogle Scholar
  • 42 Gulliver W, Zouboulis C, Prens E. et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 2016; 17: 343-351
    CrossrefPubMedGoogle Scholar
  • 43 Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol 2015; 73: 62-65
    CrossrefPubMedGoogle Scholar
  • 44 Mehdizadeh A, Hazen P, Bechara F. et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: 70-77
    CrossrefPubMedGoogle Scholar
  • 45 Falola R, DeFazio M, Anghel E. et al. What Heals Hidradenitis Suppurativa: Surgery, Immunosuppression, or Both?. Plast Reconstr Surg 2016; 138: 219-229
    CrossrefPubMedGoogle Scholar